Novel therapeutic strategies against cancer and chronic infection by targeting P-selectin glycoprotein ligand-1 as an immune T cells response regulator

Abstract

P-selectin glycoprotein ligand-1 (PSGL-1) is a homodimeric mucin-like glycoprotein primarily restricted to cells of hematopoietic origin. Although, it may be present on some non-immune cells such as epithelial cells lining the fallopian tube, microvascular endothelial cells, and platelets, PSGL-1 is broadly expressed on most immune cells including neutrophils, monocytes, dendritic cells and lymphocytes (1,2). PSGL-1 on leukocytes mediates interactions with P-selectin and E-selectin present in activated endothelium with a major role in leukocyte adhesion and transmigration as it is responsible for the initial steps of the extravasation cascade (1,2).